Cargando…

NUP62CL as an Immunological and Prognostic Biomarker of Oral Squamous Cell Carcinoma

BACKGROUND: Oral squamous cell carcinoma (OSCC) is the most common head and neck malignancy with a high mortality rate and poor prognosis. The exploration and understanding of biomarkers will help to further improve the diagnosis and treatment of OSCC. METHODS: Tumor tissue samples from 319 OSCC pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xin, Xu, Lijun, Zhou, Yongqiang, Zhou, Xiaorong, Yang, Lei, Zhou, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474866/
https://www.ncbi.nlm.nih.gov/pubmed/37663758
http://dx.doi.org/10.2147/JIR.S426277
_version_ 1785100596757397504
author Yu, Xin
Xu, Lijun
Zhou, Yongqiang
Zhou, Xiaorong
Yang, Lei
Zhou, Yan
author_facet Yu, Xin
Xu, Lijun
Zhou, Yongqiang
Zhou, Xiaorong
Yang, Lei
Zhou, Yan
author_sort Yu, Xin
collection PubMed
description BACKGROUND: Oral squamous cell carcinoma (OSCC) is the most common head and neck malignancy with a high mortality rate and poor prognosis. The exploration and understanding of biomarkers will help to further improve the diagnosis and treatment of OSCC. METHODS: Tumor tissue samples from 319 OSCC patients were retrospectively collected, along with their clinical information. In combination with bioinformatics tools and multiplex immunohistochemistry (mIHC) analyses, we evaluated NUP62CL protein expression and its relationship to tumor-infiltrating immune cells (TIICs) and immune checkpoints in the tumor microenvironment (TME), as well as its association with clinical features and prognosis of OSCC. RESULTS: We identified high-NUP62CL expression in OSCC tissues, and high-NUP62CL protein expression was associated with large tumor size, advanced clinical stage and poor prognosis. In addition, NUP62CL protein expression was positively associated with the abundance of CD3+CD4+ T cells (P<0.01), CD3+CD8+ T cells (P<0.01), CD56+ NK cells (P<0.05), CD68+CD86+ macrophages (P<0.01) and CD68+CD163+ macrophages (P<0.01), as well as the immune checkpoints, including PD-1 (P<0.001), PD-L1 (P<0.001), and CTLA-4 (P<0.001) protein expression. CONCLUSION: In conclusion, NUP62CL could be an effective prognostic and immunological biomarker for OSCC patients.
format Online
Article
Text
id pubmed-10474866
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-104748662023-09-03 NUP62CL as an Immunological and Prognostic Biomarker of Oral Squamous Cell Carcinoma Yu, Xin Xu, Lijun Zhou, Yongqiang Zhou, Xiaorong Yang, Lei Zhou, Yan J Inflamm Res Original Research BACKGROUND: Oral squamous cell carcinoma (OSCC) is the most common head and neck malignancy with a high mortality rate and poor prognosis. The exploration and understanding of biomarkers will help to further improve the diagnosis and treatment of OSCC. METHODS: Tumor tissue samples from 319 OSCC patients were retrospectively collected, along with their clinical information. In combination with bioinformatics tools and multiplex immunohistochemistry (mIHC) analyses, we evaluated NUP62CL protein expression and its relationship to tumor-infiltrating immune cells (TIICs) and immune checkpoints in the tumor microenvironment (TME), as well as its association with clinical features and prognosis of OSCC. RESULTS: We identified high-NUP62CL expression in OSCC tissues, and high-NUP62CL protein expression was associated with large tumor size, advanced clinical stage and poor prognosis. In addition, NUP62CL protein expression was positively associated with the abundance of CD3+CD4+ T cells (P<0.01), CD3+CD8+ T cells (P<0.01), CD56+ NK cells (P<0.05), CD68+CD86+ macrophages (P<0.01) and CD68+CD163+ macrophages (P<0.01), as well as the immune checkpoints, including PD-1 (P<0.001), PD-L1 (P<0.001), and CTLA-4 (P<0.001) protein expression. CONCLUSION: In conclusion, NUP62CL could be an effective prognostic and immunological biomarker for OSCC patients. Dove 2023-08-29 /pmc/articles/PMC10474866/ /pubmed/37663758 http://dx.doi.org/10.2147/JIR.S426277 Text en © 2023 Yu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yu, Xin
Xu, Lijun
Zhou, Yongqiang
Zhou, Xiaorong
Yang, Lei
Zhou, Yan
NUP62CL as an Immunological and Prognostic Biomarker of Oral Squamous Cell Carcinoma
title NUP62CL as an Immunological and Prognostic Biomarker of Oral Squamous Cell Carcinoma
title_full NUP62CL as an Immunological and Prognostic Biomarker of Oral Squamous Cell Carcinoma
title_fullStr NUP62CL as an Immunological and Prognostic Biomarker of Oral Squamous Cell Carcinoma
title_full_unstemmed NUP62CL as an Immunological and Prognostic Biomarker of Oral Squamous Cell Carcinoma
title_short NUP62CL as an Immunological and Prognostic Biomarker of Oral Squamous Cell Carcinoma
title_sort nup62cl as an immunological and prognostic biomarker of oral squamous cell carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474866/
https://www.ncbi.nlm.nih.gov/pubmed/37663758
http://dx.doi.org/10.2147/JIR.S426277
work_keys_str_mv AT yuxin nup62clasanimmunologicalandprognosticbiomarkeroforalsquamouscellcarcinoma
AT xulijun nup62clasanimmunologicalandprognosticbiomarkeroforalsquamouscellcarcinoma
AT zhouyongqiang nup62clasanimmunologicalandprognosticbiomarkeroforalsquamouscellcarcinoma
AT zhouxiaorong nup62clasanimmunologicalandprognosticbiomarkeroforalsquamouscellcarcinoma
AT yanglei nup62clasanimmunologicalandprognosticbiomarkeroforalsquamouscellcarcinoma
AT zhouyan nup62clasanimmunologicalandprognosticbiomarkeroforalsquamouscellcarcinoma